Home Search

multiple myeloma - search results

If you're not happy with the results, please do another search
CAR T-Cell Immunotherapy

Therapies That Engage T Cells Most Effective Against Relapsed or Refractory Multiple Myeloma

A new multi-center study has found that therapies which engage T cells such as bispecific antibodies and CAR-T cell therapies exhibit the most durable response in patients with relapsed or refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy.
Micrograph of myeloma neoplasm from bone marrow biopsy

Gene Signature Found for Selinexor Response in Multiple Myeloma

Mount Sinai researchers have identified three genes that predict a good response to Selinexor, a new therapy for multiple myeloma that can have serious side effects for some patients.
Micrograph of myeloma neoplasm from bone marrow biopsy

Multiple Myeloma Five-Drug Combo Therapy Shows Positive Results

An innovative method testing a five-drug combination against the findings of an earlier study, rather than a control group, proved effective at prolonging survival in patients with high-risk multiple myeloma.
Micrograph of myeloma neoplasm from bone marrow biopsy

Multiple Myeloma Subtypes Identified by New Model

For the model, researchers analyzed five different types of data obtained from DNA and RNA sequencing of 655 newly diagnosed multiple myeloma patients. The analysis identified three main groups and 12 subgroups enriched for distinct genetic and molecular features
CART Cell Cancer Immunotherapy

FDA Approves CAR T-Cell Therapy for Multiple Myeloma

BMS/bluebird bio's CAR-T cell therapy Abecma was approved by the FDA for patients with multiple myeloma whose cancer has not responded or recurred after at least four types of therapy. It is a highly personalized autologous therapy and the first CAR-T cell treatment to target myeloma and the B-cell maturation antigen.
CART Cell Cancer Immunotherapy

Multiple Myeloma CAR T-Cell Therapy Achieves Response in 73% of Patients

A new CAR T-cell therapy for multiple myeloma, idecabtagene vicleucel, induced at least a partial response in 73% of patients with the blood cancer and a complete response in 33%. Manufacturers Bristol Myers Squibb and bluebird bio now plan to seek FDA approval for this therapy.
Micrograph of myeloma neoplasm from bone marrow biopsy

Targeted Multiple Myeloma Treatment Silences IRF4 Gene

The research centered on an oligonucleotide—an investigational antisense medicine developed by Ionis Pharmaceuticals—which lowered disease burden, reduced myeloma stem cell abundance, and increased survival of mice bearing human myeloma, according to preclinical study data.

Dana-Farber, MMRF Partner to ID Markers for Multiple Myeloma Precursor

MMRF and Dana-Farber have launched a research collaboration, through which 500 SMM patients enrolled in Dana-Farber’s PROMISE study or PCROWD study will be able to join the MMRF’s CureCloud study and donate their blood samples and medical records.
Woman In The Network

GNS Healthcare Launches In Silico Multiple Myeloma “Patient”

The company says the model has multiple applications for precision medicine including discovering markers of response and nonresponse for clinical trial design, predicting optimal combination therapies, and running head-to-head in silico trials.
Micrograph of myeloma neoplasm from bone marrow biopsy

GNS Healthcare, Partners Identify Transcription Factor Linked to Multiple Myeloma

GNS Healthcare and partners said the identification of PHF19 could lead to improvements in how diagnostics developers target the transcription factor through single gene tests—as well as how researchers design clinical trials, and how oncologists make decisions on treating patients with newly diagnosed multiple myeloma.

Trending

Inside Precision Medicine